C
Cristina Queralt
Researcher at Laboratory of Molecular Biology
Publications - 43
Citations - 9876
Cristina Queralt is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 20, co-authored 43 publications receiving 9079 citations. Previous affiliations of Cristina Queralt include Autonomous University of Barcelona.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell,Teresa Moran,Cristina Queralt,Rut Porta,Felipe Cardenal,Carlos Camps,Margarita Majem,Guillermo Lopez-Vivanco,Dolores Isla,Mariano Provencio,A. Insa,Bartomeu Massuti,José Luis González-Larriba,Luis Paz-Ares,Isabel Bover,Rosario García-Campelo,Miguel Angel Moreno,Silvia Catot,Christian Rolfo,Noemi Reguart,Ramon Palmero,Jose Miguel Sanchez,Roman Bastus,Clara Mayo,Jordi Bertran-Alamillo,Miguel Angel Molina,Jose Javier Sanchez,Miquel Taron +27 more
TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.
Journal ArticleDOI
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas
Miguel Taron,Yukito Ichinose,Rafael Rosell,Tony Mok,Bartomeu Massuti,Lurdes Zamora,Jose Luis Mate,Christian Manegold,Mayumi Ono,Cristina Queralt,Thierry Jahan,Jose Javier Sanchez,Maria Sanchez-Ronco,Victor Hsue,David M. Jablons,Jose Miguel Sanchez,Teresa Moran +16 more
TL;DR: The presence of EG FR mutations is a major determinant of gefitinib response, and targeting EGFR should be considered in preference to chemotherapy as first-line treatment in lung adenocarcinomas that have demonstrable EGFR mutations.
Journal ArticleDOI
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R. Porta,J.M. Sánchez-Torres,Luis Paz-Ares,Bartomeu Massuti,Noemi Reguart,Clara Mayo,Pilar Lianes,Cristina Queralt,V. Guillem,Pablo Herrera Salinas,Silvia Catot,Dolores Isla,A. Pradas,Alfonso Gurpide,J. de Castro,E Polo,Teresa Puig,Miquel Taron,Ramon Colomer,Rafael Rosell +19 more
TL;DR: Erlotinib is active in brain metastases from NSCLC; this clinical benefit is related to the presence of activating mutations in exons 19 or 21 of the EGFR gene.
Journal ArticleDOI
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
Miquel Taron,Rafael Rosell,Enriqueta Felip,Pedro Mendez,John Souglakos,Maria Sanchez Ronco,Cristina Queralt,Joaquim Majó,Jose Miguel Sanchez,Jose Javier Sanchez,José Maestre +10 more
TL;DR: BRCA1 expression is potentially an important tool for use in cancer management and should be assessed for predicting differential chemosensitivity and tailoring chemotherapy in lung cancer.